According to the American Diabetes Association, the first-line glycemic control therapy focuses on comorbidities, lifestyle modification, and medications such as metformin and combination therapy with GLP-1 RAs and sodium-glucose cotransporter-2 (SGLT-2) inhibitors [18]. This evidence concerns the gene SLC5A2 and diabetes mellitus.